Spots Global Cancer Trial Database for Phase I Study of S64315 Administred Intravenously in Patients With Acute Myeloid Leukaemia or Myelodysplastic Syndrome
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Phase I Study of S64315 Administred Intravenously in Patients With Acute Myeloid Leukaemia or Myelodysplastic Syndrome
Official Title: Phase I, International, Multicentre, Open-label, Non-randomised, Non-comparative Study of Intravenously Administered S64315, a Mcl-1 Inhibitor, in Patients With Acute Myeloid Leukaemia (AML) or Myelodysplastic Syndrome (MDS)
Study ID: NCT02979366
Study Description
Brief Summary: The CL1-64315-001 study is a phase I, international, multicentre, open-label, non-randomised, non-comparative study. This study is designed in two parts: one part for dose escalation, one part for dose expansion.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Patient Care Location: Smilow Cancer Hospital at Yale, New Haven, Connecticut, United States
The University of Texas MD Anderson Cancer Center, Department of Leukemia, Division of Cancer Medicine, Houston, Texas, United States
The Alfred Hospital Department of Haematology, Melbourne, , Australia
Royal Melbourne Hospital, Department of Clinical Haematology and BMT Service, Melbourne, , Australia
Institut Paoli-Calmettes Departement d'Hématologie, Marseille, , France
Hôpital Saint-Antoine Département d'Hematologie Clinique et de Thérapie cellulaire, Paris, , France
Institut Universitaire du Cancer Toulouse Oncopole, Toulouse, , France
Hospital Universitario Vall d' Hebron/VHIO Hematology Department, Barcelona, , Spain
Hospital Universitario La Fe Hematology Department, Valencia, , Spain
Contact Details
Name: Andrew WEI
Affiliation: The Alfred Hospital, Melbourne, Victoria
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
